Fedratinib Alternatives Compared
| Fedratinib | Jakafi (ruxolitinib) | Ruxolitinib |
|
|---|
| Fedratinib | Jakafi (ruxolitinib) | Ruxolitinib |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myelofibrosis. Fedratinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Jakafi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Ruxolitinib may also be used for purposes not listed in this medication guide. |
Related suggestions Myelofibrosis
|
|||||||
| More about Fedratinib | More about Jakafi (ruxolitinib) | More about Ruxolitinib | ||||||||
| Ratings & Reviews | ||||||||||
|
Fedratinib has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect. |
Ruxolitinib has an average rating of 7.3 out of 10 from a total of 43 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Fedratinib side effects |
View all Jakafi side effects |
View all Ruxolitinib side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Inrebic |
N/A |
Jakafi | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
114 hours |
5.8 hours |
5.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 561 drugs are known to interact with Fedratinib:
|
A total of 512 drugs are known to interact with Jakafi:
|
A total of 512 drugs are known to interact with Ruxolitinib:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
|
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
August 16, 2019 |
November 16, 2011 |
November 16, 2011 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Ojjaara
Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.